Heparan sulfate gets specific by Dove, Alan W.
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Another Notch in CD44
 
lthough the cellular adhesion molecule CD44 is involved 
in processes ranging from lymphocyte homing to tumor 
metastasis, it has remained unclear how CD44 transduces the 
intracellular signals required for such a broad range of activities. 
On page 755, Okamoto et al. propose a surprising mechanism 
for CD44 signal transduction: a cytoplasmic domain is cleaved 
from the protein, after which it translocates to the nucleus and 
acts directly as a transcriptional regulator.
Previous work demonstrated 
that the extracellular domain 
of CD44 can be cleaved by 
membrane-associated 
proteases, regulating the inter-
action between CD44 and the 
extracellular matrix. Okamoto 
et al. identified a subsequent 
proteolytic cleavage that 
releases a fragment of the 
CD44 intracellular domain 
(CD44ICD). This fragment 
translocates to the nucleus, 
where it activates transcription 
from the TPA-responsive transcriptional regulation elements 
found in front of a variety of cellular genes. CD44ICD over-
expression also induces CD44 mRNA expression, suggesting 
a feedback mechanism to regulate CD44 levels. In addition to 
illuminating the mechanism of CD44 signaling, the new work 
provides the first example of an adhesion molecule using a 
type of signal transduction first described for Notch, in which 
a cleavage fragment of a membrane receptor serves as a 
transcriptional activator. 
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CD44 can enter and signal in 
the nucleus.
 
The leg bone’s connected 
to the…cerebellum?
 
n a result that bodes well for 
medical applications of stem 
cells, Priller et al. report on page 
733 that bone marrow-derived 
stem cells can differentiate into 
apparently normal Purkinje 
neurons in an adult mouse 
brain. Although previous work 
demonstrated that bone marrow 
transferred into an irradiated 
mouse could give rise to cells 
I
A bone marrow cell (yellow) 
can develop into a functional 
Purkinje neuron.
 
expressing neuronal markers, the authors are the first to identify 
donor-derived neurons that appear to be morphologically normal 
and functional, and to determine that the donor-derived cells 
survive as the mouse ages.
The authors transferred the green fluorescent protein (GFP) 
gene into donor bone marrow cells, and then identified GFP-
expressing cells in the brains of mice that received the transplanted 
bone marrow. Donor-derived Purkinje cells were not seen four 
months after transplantation, but had appeared by 12 months 
posttransplantation and persisted at least three months beyond 
that, observations that encompassed most of the lifespan of the 
mice. Priller et al. speculate that the delayed colonization of the 
cerebellum by the donor cells may be due to the death of the 
recipient’s original Purkinje cells during aging. If true, this model 
suggests that bone marrow-derived stem cells might be able to 
preferentially regenerate neurons lost to aging or disease.
 
 
 
 
 
Heparan sulfate gets speciﬁc
 
roteoglycans on the cell surface can exhibit a baffling diversity 
of structures, but the relative importance of that diversity in 
controlling the specificity of interactions between proteins is not 
known. On page 845, Allen et al. demonstrate that heparan 
sulfate serves as a tissue-specific regulator of interactions between 
FGF family members and FGF receptors. Besides providing 
important insight into the mechanism of FGF signaling, the work 
suggests that specific heparan sulfate sequences on a cell’s surface 
can determine the cell’s ability to respond to exogenous signals.
The formation of an FGF signaling complex requires that both 
an FGF-family protein and its receptor interact with a heparan 
sulfate proteoglycan, but little was known about the function of 
heparan sulfate in this complex. The authors probed frozen tissue 
sections of mouse embryos with FGF-2 and FGF-4 to detect heparan 
sulfate expression patterns, and also examined the ability of two FGF 
receptor constructs to promote FGF signaling complex formation.
FGF-2 and FGF-4 bind to many of the same tissues, but FGF-4 
does not recognize heparan sulfate in the heart or major blood vessels. 
One of the two FGF receptor constructs also demonstrated
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less promiscuous complex-
forming activity than the 
other. The results suggest that 
FGF-2, FGF-4, and FGF 
receptors recognize different 
forms of heparan sulfate 
that are expressed in a 
tissue-specific manner. 
The authors have now 
expanded their analysis to 
include five different FGFs 
and four different receptors, 
and have determined that 
both FGFs and FGF 
FGF-4 binds lung (bottom) but 
not heart (top), whereas FGF-2 
binds both.
 
receptors seek specific binding sites on heparan sulfate, displaying 
a binding pattern that changes during the course of development. 
Because heparan sulfate is also a ligand for a variety of growth 
factors and viruses, the findings imply a wide range of specific 
functions for proteoglycans.
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